Key facts
- Developer of a novel, non-invasive sustained drug delivery platform designed to deliver medication to the surface of the eye for improved treatment of ocular conditions.
- It has raised $13.7M across 3 recorded rounds; the latest was Early Stage VC ($9.9M) in Sep 2025.
- Mati Therapeutics has filed 6 Form Ds with the SEC since 2013, most recently Oct 2025 ($9.9M sold to 13 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Mati Therapeutics
Create free account
No card required
Funding rounds
3 roundsAbout Mati Therapeutics
Developer of a novel, non-invasive sustained drug delivery platform designed to deliver medication to the surface of the eye for improved treatment of ocular conditions. The company's platform offers a platform that provides controlled, long-lasting drug release, reducing the need for frequent dosing, enabling patients with glaucoma, dry eye syndrome, ocular allergies, and post-cataract surgery care to experience enhanced treatment adherence and effectiveness.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2012
- Employees
- 10
- Website
- matitherapeutics.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Mati Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.